Si-Bone director Jeffrey Dunn sells $378,160 of common stock
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 20,000 shares of company stock for $378,160 on September 1, 2026, following the exercise of stock options. This sale, conducted under a Rule 10b5-1 plan, occurred after a significant 27% return in SIBN stock over six months, though it's noted the stock is trading above its Fair Value. The company recently reported strong Q2 2026 results, exceeding analyst expectations with increased revenue and adjusted loss per share.
Si-Bone director Jeffrey Dunn sells $378,160 of common stock By Investing.com
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 20,000 shares of common stock for approximately $378,160 on September 1, 2026, under a Rule 10b5-1 trading plan. This sale followed his exercise of stock options at a lower price. Despite the stock's strong performance, InvestingPro suggests it's trading above its Fair Value, while the company recently exceeded Q2 2026 financial expectations.
SI-BONE Director Jeffrey Dunn Announces Stock Option Exercises and Sales Under 10b5-1 Plan
SI-BONE, Inc. director Jeffrey W. Dunn exercised stock options and subsequently sold 20,000 shares of common stock on September 1, 2026, under a pre-arranged 10b5-1 trading plan. The shares were acquired at an exercise price of $4.68 each and sold at a weighted-average price of $18.908 per share. After these transactions, Dunn directly holds 16,057 shares and indirectly holds 81,073 shares through a living trust.
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference. The company's management will host a fireside chat on September 14, 2026, at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time. The conference will take place in New York, NY.
Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?
Si-Bone (SIBN) has been identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of B. The article highlights its recent positive price performance, outperforming both its industry and the S&P 500 over various periods. Additionally, positive earnings estimate revisions further support its promising outlook for investors seeking near-term growth.
SI-BONE (NASDAQ: SIBN) trust to sell 25,972 shares under Rule 144
The DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003, associated with SI-BONE, Inc. (SIBN), has filed to sell 25,972 shares of common stock under Rule 144. These shares were acquired through the vesting of restricted stock units between May 15, 2021, and November 15, 2025. The filing also details prior sales made by the trust and Laura Francis, including significant Rule 10b5-1 transactions in August 2026.
SI-BONE officer plans $232K sale of 11,636 shares | SIBN SEC Filing - Form 144
An officer at SI-BONE, Inc. (SIBN), Anshul Maheshwari, has filed a Form 144 notice to sell 11,636 shares of common stock, valued at approximately $232,254.56, through Morgan Stanley Smith Barney LLC. The sale is planned for on or before August 24, 2026, on NASDAQ. These shares were acquired from the vesting of restricted stock units (RSUs) and performance stock units (PSUs) between January 1, 2025, and February 15, 2026.
This Insider Has Just Sold Shares In SI-BONE
SI-BONE's CEO & Director, Laura Francis, recently sold US$279k worth of stock at US$18.66 per share, reducing her total holding by 2.8%. This follows a larger sale earlier in the year of US$1.4m worth of shares at a lower price of US$15.44. While insiders own about 3.6% of the company, the consistent selling without any purchases suggests caution for potential investors.
Si-Bone CEO Laura Francis sells over $1 million in company stock
Si-Bone CEO Laura Francis sold over $1 million worth of company stock in transactions occurring on August 20 and 21, 2026, under a pre-arranged trading plan. This sale comes as SI-BONE shares have seen significant gains, though InvestingPro analysis suggests the stock may be overvalued. Despite recent positive financial results and raised guidance, the stock declined after hours due to investor consideration of future outlook and spending plans.
ETFs Investing in SI-BONE, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold SI-BONE, Inc. stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, and AUM for each. The funds are primarily small-cap and healthcare-focused, offering investors diversification and accessibility to SI-BONE, Inc. shares. Key issuers include BlackRock, State Street Corp., The Vanguard Group, and Goldman Sachs, among others.
Si-Bone CEO Laura Francis sells over $1 million in company stock
Si-Bone CEO Laura Francis recently sold over $1 million worth of company stock in transactions occurring on August 20 and 21, 2026, under a pre-arranged 10b5-1 trading plan. These sales followed strong stock performance and came shortly after the company reported better-than-expected Q2 2026 financial results, though the stock saw a decline in after-hours trading. Francis still holds a significant number of shares both directly and indirectly.
Si-Bone chief op & financial officer sells $337,138 in stock
Anshul Maheshwari, Chief Operating and Financial Officer at SI-BONE, Inc. (NASDAQ:SIBN), sold 16,975 shares of the company’s common stock for a total of $337,138 in transactions on August 19 and August 21, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan, following recent strong stock performance and positive Q2 2026 earnings results. After these sales, Mr. Maheshwari beneficially owns 234,920 shares of SI-BONE.
Si-Bone Insider Sold Shares Worth $1,088,201, According to a Recent SEC Filing
An insider at Si-Bone (SIBN) recently sold shares valued at $1,088,201, as disclosed in a recent SEC filing. This transaction occurred on August 21, 2026. The article notes that this is part of a broader set of insider transactions and analyst updates for the company, including recent price target adjustments and earnings reports.
SI-BONE (NASDAQ: SIBN) CFO sells 16,975 shares at $19.55 and $20.02
SI-BONE, Inc.'s Chief Op & Financial Officer, Anshul Maheshwari, sold a total of 16,975 shares of company common stock through open-market transactions on August 19 and August 21, 2026. These sales were conducted under a Rule 10b5-1 trading plan established on December 17, 2025. Following these transactions, Maheshwari's direct holdings include 167,604 shares issuable upon the settlement of restricted stock units.
SI-BONE (SIBN) trust to sell 3,923 shares from stock units
The DAVID & LAURA FRANCIS JOINT REVOCABLE TRUST intends to sell 3,923 shares of SI-BONE (SIBN) common stock, valued at $76,420.04, through Morgan Stanley Smith Barney LLC under Rule 144. These shares originate from Performance Stock Units (1,901 shares) and Restricted Stock Units (2,022 shares). The filing also notes previous sales by the trust and Laura Francis within the last three months, including a 10b5-1 sale of 51,884 shares for over $1 million.
SI-BONE (NASDAQ: SIBN) insider lines up new sale after plan trades
An insider at SI-BONE, Inc. (SIBN), Anshul Maheshwari, has filed a Rule 144 notice to sell 11,228 shares of common stock, valued at $218,721.44. These shares were acquired through the vesting of restricted and performance stock units between January 2025 and February 2026. This proposed sale follows several thousand shares already sold under a 10b5-1 trading plan in the past three months.
SI-BONE (NASDAQ: SIBN) affiliate plans $110K stock sale
An affiliate of SI-BONE, Inc. (SIBN), Anshul Maheshwari, has filed a Form 144 notice to sell up to 5,747 shares of common stock, valued at approximately $110,000. These shares were acquired through the vesting of restricted stock units between April 1, 2026, and August 15, 2026. The proposed sale is scheduled for August 19, 2026, through Morgan Stanley Smith Barney LLC, and follows previous sales by Maheshwari in the past three months.
SI-BONE (NASDAQ: SIBN) CFO holds 167,604 RSU shares after tax sales
SI-BONE, Inc. (SIBN) CFO Anshul Maheshwari sold 4,665 shares of common stock on August 17, 2026, in two "sell to cover" transactions to satisfy tax obligations from vesting restricted stock units. Following these non-discretionary sales, Maheshwari retains holdings including 167,604 shares issuable upon settlement of restricted stock units. The sales were executed at weighted average prices of $18.6798 and $18.6224.
SI-BONE (NASDAQ: SIBN) officer’s tax sale leaves 130K+ stock units
Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer at SI-BONE, Inc. (SIBN), sold 3,725 shares of common stock on August 17, 2026. These sales were non-discretionary "sell to cover" transactions to meet tax withholding obligations from vesting restricted stock units. Following these sales, Pisetsky retains 130,281 shares issuable upon settlement of restricted stock units.
Cadian Capital discloses 7.5% SI-BONE (SIBN) ownership in Schedule 13G filing
Cadian Capital Management, LP, along with Cadian Capital Management GP, LLC, and Eric Bannasch, has reported a 7.5% passive ownership stake in SI-BONE, Inc. (SIBN) through a Schedule 13G filing. As of June 30, 2026, the reporting persons beneficially owned 3,347,574 shares of SI-BONE common stock. These shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, with Cadian Capital Management, LP exercising exclusive voting and investment power.
(SIBN) and the Role of Price-Sensitive Allocations
This article provides a quantitative analysis of Si-bone Inc. (NASDAQ: SIBN), highlighting strong near and mid-term sentiment which could extend long-term, and notes compelling upside potential due to the absence of upper resistance levels. It outlines three AI-generated trading strategies with specific entry, target, and stop-loss zones for different risk profiles. The analysis also includes a multi-timeframe signal breakdown for near, mid, and long-term horizons.
The SI-BONE, Inc. (NASDAQ:SIBN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
SI-BONE, Inc. reported second-quarter results showing revenues of US$56m, in line with analyst predictions, and smaller-than-expected statutory losses of US$0.09 per share. Analysts have slightly upgraded their sentiment for the company, particularly concerning loss per share forecasts for the year. Despite the improved loss estimates, the consensus price target of US$25.00 remains unchanged, indicating no significant long-term impact on the stock's valuation.
The SI-BONE, Inc. (NASDAQ:SIBN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
SI-BONE, Inc. reported second-quarter results showing revenues in line with analyst predictions and smaller-than-expected statutory losses. Analysts have moderately uplifted their sentiment, improving loss per share forecasts for 2026, though the consensus price target of US$25.00 remains unchanged. The company is forecast to grow substantially faster than its industry, with an 18% annualised revenue growth to the end of 2026.
BlackRock, Inc. Adds to SI-BONE Inc (SIBN) Stake -- Shares Trade 13% Below GF Value
BlackRock, Inc. has increased its stake in SI-BONE Inc (SIBN), a medical device company, by purchasing 130,194 additional shares. This transaction suggests SI-BONE is "Modestly Undervalued" according to GuruFocus's GF Valuation, trading approximately 13% below its intrinsic value. Despite current profitability concerns, the move aligns with BlackRock's strategy of identifying undervalued opportunities in high-growth sectors, and SI-BONE shows strong growth metrics and institutional interest.
SI-BONE, Inc. (SIBN) director sells 20,000 shares after option exercise
SI-BONE director Jeffrey W. Dunn exercised stock options for 20,000 shares at $4.68 per share and simultaneously sold all 20,000 shares at a weighted-average price of $18.4607. These transactions were executed on August 3, 2026, under a Rule 10b5-1 trading plan established on May 7, 2025. After these trades, Dunn directly holds 106,260 shares and indirectly holds 81,073 shares through a living trust.
SI-BONE, Inc. 2026: Revenue $56.01M, EPS ($0.09) — 10-Q Summary
SI-BONE, Inc. reported strong financial results for the quarter ended 2026, with revenue increasing by 15.2% year-over-year to $56.01M and a significant reduction in net loss and diluted EPS. The company highlighted revenue growth driven by increased procedure volume, a shift towards ASCs and OBLs, and strategic investments in R&D and sales expansion, including three FDA Breakthrough Device designations.
SI-BONE, Inc. Q2 2026 Earnings Call Summary
SI-BONE, Inc. reported strong Q2 2026 earnings driven by 9% sequential U.S. volume growth and 26% international growth, attributing success to its hybrid commercial model and expanded product portfolio. The company is strategically shifting to a broader spinopelvic focus, with plans for a third breakthrough device launch in Q4 2026 and increased R&D investment. Management anticipates positive impacts from new CMS reimbursement increases and aims for nearly 100 territories by year-end.
SI-BONE, Inc. Stock 12‑Month Price Target Raised to $25, Implies 36% Upside
Analysts have raised the 12-month price target for SI-BONE, Inc. (SIBN) stock from $24.44 to $25, with an implied potential upside of approximately 36% based on the recent closing price. The consensus rating among 9 covering analysts remains a "Buy," with no "Holds" or "Sells."
UBS Lifts Price Target on SI-BONE to $25 From $24, Maintains Buy Rating
UBS has increased its price target for SI-BONE (SIBN) shares to $25 from $24, while maintaining a Buy rating on the stock. This adjustment follows SI-BONE's recent Q2 2026 earnings report, where
Canaccord reiterates SI-BONE stock rating on strong Q2 results
Canaccord Genuity has reiterated a Buy rating and a $27.00 price target for SI-BONE Inc. (NASDAQ:SIBN) following strong Q2 2026 results where the company beat bottom-line expectations and raised revenue guidance. Despite the positive performance and financial flexibility from holding more cash than debt, the stock experienced a decline in after-hours trading, suggesting investor concerns about the company's outlook and spending plans. SI-BONE is also expanding its international presence and investing in internal capabilities, with anticipated growth from new product clearances and distribution partnerships.
SI-BONE Reports Q2 2026: $56.0M Revenue, Positive Adjusted EBITDA of $2.8M, Raises 2026 Revenue Guidance
SI-BONE (SIBN) reported strong second-quarter 2026 results, with revenue of $56.0 million, a 15.2% year-over-year increase, and positive adjusted EBITDA of $2.8 million. The company also improved its net loss and increased its full-year 2026 revenue guidance to $231 million–$233 million, driven by growth in U.S. procedure volumes and international markets. Key highlights include an expanding active U.S. physician base and progress in product development and reimbursement.
Truist Adjusts Price Target on SI-BONE to $23 From $21, Maintains Buy Rating
Truist has increased its price target for SI-BONE (SIBN) shares to $23 from $21, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the firm regarding the medical device company. The article, published by MT Newswires on MarketScreener, indicates a continued positive sentiment from Truist towards SI-BONE.
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. reported strong financial results for the second quarter of 2026, including a 15.2% increase in worldwide revenue to $56.0 million and a 178% improvement in adjusted EBITDA to $2.8 million. The company also raised its fiscal year 2026 revenue guidance to a range of $231 million to $233 million, reflecting confidence in its growth trajectory. Key operational highlights included a 19% increase in active U.S. physicians and positive cash flow from operations, driven by robust demand for its procedural solutions for compromised bone.
SIBN Looks 10.6% Undervalued on GF Value™ Despite Unprofitability
SI-BONE Inc. (SIBN) has reaffirmed its fiscal 2026 gross margin guidance at 79% and lowered its operating expense forecast to 12%, demonstrating a focus on cost optimization despite being unprofitable. The company's Price-to-Sales ratio of 3.91 is below its historical median, indicating tempered market expectations, although its GF Value™ suggests it is 10.6% undervalued. SIBN holds a GF Score™ of 80/100, driven by strong growth and valuation, but is tempered by weak profitability and mixed insider and guru activity.
SIBN Q2 FY2026 earnings call
SI-BONE, Inc. reported strong Q2 FY2026 results with worldwide revenue of $56.0 million, up 15.2% year-over-year, and a significant improvement in adjusted EBITDA. The company saw robust U.S. procedure volume growth and is on track for a phased commercial launch of its third breakthrough device in Q4. SI-BONE raised its full-year 2026 revenue guidance and discussed strategic initiatives including increased R&D investment, commercial expansion, and new product development to drive future growth and operating leverage.
Earnings call transcript: SI-BONE tops Q2 2026 estimates, shares fall after hours
SI-BONE (SIBN) exceeded Wall Street's expectations for Q2 2026, reporting a smaller adjusted loss and slightly higher revenue due to strong procedure volumes and improved efficiency. Despite the beat, the company's shares fell in after-hours trading as investors focused on the future outlook and increased spending plans. SI-BONE raised the low end of its full-year 2026 revenue guidance and anticipates continued growth driven by new product launches, improving reimbursement, and expanded commercial capacity.
SI-BONE raises 2026 worldwide revenue outlook to $231 million-$233 million
SI-BONE has increased its 2026 worldwide revenue guidance to $231-$233 million, representing a 15%-16% year-over-year growth from its previous outlook of $230-$233 million. The company maintained its gross margin outlook at approximately 79% and revised operating expense expectations to about 12% at the midpoint. This update follows a strong Q2 performance with $56 million in revenue, a 15.2% increase, and a gross margin of 79.5%.
Earnings Flash (SIBN) SI-BONE, Inc. Reports Q2 Revenue $56.0M, vs. FactSet Est of $55.3M
SI-BONE, Inc. reported its second-quarter revenue of $56.0 million, surpassing the FactSet estimate of $55.3 million. The medical device company also posted a Q2 loss of $0.09 per share, which was better than the FactSet estimate of a $0.15 loss. These results were published on August 3, 2026.
SI-BONE Q2 2026 Earnings: Revenue Rises 15.2% as Loss Narrows
SI-BONE reported strong Q2 2026 results with a 15.2% increase in revenue to $56.0 million and a narrowed diluted loss per share to $0.09. The company's U.S. procedure growth was a key driver, supported by an expanding physician base and increased territory productivity. SI-BONE also provided an updated 2026 guidance, modestly raising the lower end of its full-year revenue range and reducing expected operating-expense growth.
SIBN Looks 10.6% Undervalued on GF Value™ Amid Strong Growth Prospects
SI-BONE Inc (SIBN) reported Q2 revenue of $56 million, exceeding analyst expectations
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) reported a Q2 loss of $0.09 per share, exceeding the Zacks Consensus Estimate of a $0.15 loss and surpassing last year's $0.14 loss. The medical device maker also topped revenue estimates with $56.01 million, outperforming the $48.63 million from the previous year. Despite outperforming expectations, Si-Bone's shares have decreased by 9.9% year-to-date, while the S&P 500 gained 9.4%.
Responsive Playbooks and the SIBN Inflection
This article analyzes Si-bone Inc. (NASDAQ: SIBN) using AI models, highlighting a strong near-term sentiment but neutral mid and long-term outlook. It identifies resistance being tested and presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
SI-BONE (Nasdaq:SIBN) - Stock Analysis
This report provides a comprehensive stock analysis of SI-BONE (SIBN), a medical device company. It covers the company's market overview, valuation, future growth prospects, past performance, financial health, dividend policy, management, and ownership. The analysis highlights that SIBN is currently unprofitable but trading below its estimated fair value, with significant insider selling observed over the past three months.
SI-BONE Number of Employees 2026 | Employee Count & Headcount Data
SI-BONE, Inc. (SIBN) had approximately 385 employees worldwide as of March 2026, representing a 7.9% growth since 2023. The company is actively hiring, with 46 active job postings in 2026, a 96.8% increase from the previous year. Most of its workforce is located in North America, and the average salary is $121,509.
BlackRock, Inc. (SIBN) discloses 3.56M-share, 8% passive stake in SI-BONE
BlackRock, Inc. has disclosed an 8% passive stake in SI-BONE, Inc. common stock, totaling 3,558,735 shares as of June 30, 2026. This ownership, reported in an Amendment No. 7 to Schedule 13G, indicates BlackRock's sole voting power over 3,490,613 shares and sole dispositive power over all 3,558,735 shares. No single underlying client of BlackRock holds more than 5% of SI-BONE's outstanding shares.
Earnings Preview: Si-Bone to Report Financial Results Post-market on August 03
This article announces that Si-Bone (NASDAQ: SIBN) is scheduled to release its financial results after market close on August 3. The company is expected to report an EPS of -$0.30 and revenue of $37.58 million, according to analyst estimates. These figures will be compared against previous quarters and year-ago results to gauge the company's performance.
SIBN Initiated Coverage by UBS -- Price Target Announced at $24
UBS has initiated coverage on SI-BONE (SIBN) with a "Buy" rating and a price target of $24.00, suggesting significant upside potential. GuruFocus assesses SIBN as 13.1% undervalued with a GF Value™ of $20.59, despite the company currently being unprofitable. The stock boasts a strong GF Score™ of 80/100, driven by high growth and valuation ranks, though its profitability remains a concern.
SI-BONE Inc (SIBN) Financial Health: Profitability & Balance Sheet Analysis
SI-BONE Inc (SIBN) currently holds a financial score of 7.73, ranking 61st out of 199 in the Healthcare Equipment & Supplies industry. The company exhibits robust financial status and high operating efficiency, with its latest quarterly revenue climbing 11.20% year-over-year to $52.59 million, and net profit increasing by 33.75% year-over-year. The report details various financial health dimensions, though specific data for some metrics have not yet been disclosed by the company.
SI-BONE Inc (SIBN) Institutional Confidence
SI-BONE Inc (SIBN) has an institutional shareholding score of 10.00, placing it first within the Healthcare Equipment & Supplies industry. Institutional shareholding stands at 103.63%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder, holding 733.75K shares, representing 1.90% of outstanding shares.
SI-BONE Inc (SIBN) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for SI-BONE Inc (SIBN), covering operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes for various cash flow components. The report also includes an FAQ section defining different types of cash flow and specific figures for SI-BONE Inc's recent performance.
